Cryo-Save N.V. has acquired Salveo Biotechnology SA
December 2013 — Cryo-Save N.V. (Cryo-Save), the largest family stem cell bank in Europe, has acquired Salveo Biotechnology SA, the cord banking activities of Salveo Holding SA (Salveo), for an undisclosed consideration.
Cryo-Save is the leading international stem cell storage brand. It offers collection, analysis, processing and cryogenic preservation of stem cells obtained from the umbilical cord and from umbilical cord blood that can be used in medical therapies later in a child’s lifetime.
Salveo Biotechnology SA is the umbilical cord blood and umbilical cord tissue cryopreservation division of Salveo Holding SA, a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine.
Salveo Holding SA is a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine. Founded in 2011 and made up of experts in regenerative medicine, the group is also present in Italy, Spain, Portugal and Ukraine and has developed a dynamic and professional commercial network.
Salveo was selected to partner with Cryo-Save, acquiring all assets related to the distribution and commercial activities of Salveo's umbilical cord blood and umbilical cord tissue cryopreservation business. Frédéric Amar, CEO of Salveo, has also joined the board of Cryo-Save as non-Executive Director.
Our role in the transaction
Oaklins' team in the Netherlands identified potential partners, initiated contact and led talks on potential cooperation with a number of parties and advised the buyer in this transaction.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more